SIBO Is Real. But It Is Also Overdiagnosed, Poorly Understood, and Too Often Treated Superficially.
At Endometriosis Surgical Specialists International (ESSI), we see a recurring pattern in patients presenting with bloating, constipation, abdominal pressure, pelvic pain, and bowel dysfunction: very quickly, the conversation with their previous doctors becomes about SIBO (Small Intestinal Bacterial Overgrowth).
That may sound like progress. It may sound like a precise diagnosis. But in many patients, it is not.
The problem is not that SIBO does not exist. It does. The problem is that SIBO has become a dangerously convenient diagnosis in a clinical space full of uncertainty. Once the label is applied, many patients are placed on repeated courses of antibiotics without anyone seriously asking the harder and more important question: Why did the overgrowth happen in the first place?
If that question is never answered, treatment becomes repetitive instead of intelligent. Symptoms recur, microbiomes are disrupted, diets become increasingly restricted, and patients are left on a devastating cycle of temporary improvement followed by relapse.
That is not good medicine. Here is why the current approach to SIBO is failing patients, and how we view this complex issue at ESSI.
The Diagnostic Flaw: We Still Lack a True Gold Standard
One of the primary reasons SIBO remains so controversial in gastroenterology is that we still do not have a truly satisfying way to diagnose it.
We can identify bacterial overgrowth or fermentation patterns that suggest overgrowth. But that is not the same as proving that the overgrowth is the true driver of the patient’s symptoms. This distinction matters deeply.
A patient may have bacterial overgrowth and still not have that as the dominant cause of their bloating, pain, or constipation. Another patient may have a relatively modest abnormality on testing but major symptoms because the underlying issue is motility, visceral sensitivity, pelvic floor dysfunction, or dysbiosis—rather than simple excess bacterial quantity.
At ESSI, this is one of our most important conceptual points: finding bacteria is not the same as understanding the disease.
The Problem with Breath Testing and Transit Time
Breath testing is highly attractive because it is noninvasive. It gives the impression of being objective and feels like a neat solution to a messy problem. But it has major limitations.
The basic idea is straightforward: the patient drinks a substrate (like glucose or lactulose), and then hydrogen and methane levels are measured over time. If bacteria ferment the substrate early, it is interpreted as overgrowth in the small intestine.
In theory, this sounds elegant. In practice, interpretation is heavily dependent on transit time, which creates massive blind spots.
-
The Speed Trap: If a patient has rapid transit, the glucose may simply move quickly into the colon, where colonic bacteria normally ferment it. That can produce a hydrogen peak that looks abnormal, even though the signal is not coming from true small bowel overgrowth at all.
-
The Lactulose Problem: Lactulose testing creates even more interpretive problems because lactulose is not absorbed. It will eventually reach the colon and be fermented there regardless, making it incredibly difficult to distinguish a true early small bowel event from a normal downstream colonic one.
The clinician is left guessing: How high did the hydrogen rise? When did the peak occur? How fast was the bowel moving? Did the patient follow the prep diet? There is no perfect way to know whether that peak came from the small bowel or the colon.
While breath testing may be a useful tool, it is not a definitive answer. It should be interpreted carefully and in clinical context, not worshipped as an absolute truth.
Methane, Constipation, and the “Chicken or Egg” Dilemma
Methane-dominant testing is often associated with constipation, which is a clinically relevant observation. But even here, the conversation is oversimplified. The real questions should be:
-
Is methane driving the constipation?
-
Or is the constipation and slow transit creating the stagnant environment in which methanogens thrive?
At ESSI, we view this through a systems lens. In many patients, it makes more sense to focus first on fixing the constipation, the transit problem, the pelvic floor dysfunction, or the evacuation disorder. If motility improves, the methane pattern often improves alongside it. That is vastly different from treating methane as if it were the original disease.
The Danger of Repeated Antibiotics
This is where the diagnosis becomes dangerous. Patients are told, “You have SIBO, so you need antibiotics.” Sometimes they feel better temporarily. But if the real generator is still there—slow transit, stool retention, evacuation failure, pelvic floor dysfunction, dysmotility, or altered bowel mechanics—the overgrowth frequently returns.
The patient gets trapped in a cycle:
-
Abnormal test
-
Antibiotics
-
Temporary relief
-
Recurrence
-
Repeat antibiotics
Because repeated antibiotics are not biologically neutral, they disrupt microbial recovery, worsen tolerance to fiber, and leave the patient in a deeply frustrating paradox: they are told to rebuild their microbiome, but they can no longer tolerate the very foods supposed to help restore it.
Antibiotics may have a role, but they are not a substitute for figuring out why the bowel environment became vulnerable in the first place.
It Is Not Always the Gas. It Is the Body’s Response to the Gas.
This is one of the most underappreciated insights in the bloating world: many patients who visibly distend throughout the day—even to the point of looking pregnant—do not actually generate enough additional gas to explain the severity of the distension.
So what is happening? In many cases, it is a neuromuscular and biomechanical problem.
These patients have an abnormal visceral response to ordinary intestinal distension. Instead of accommodating normally, the abdominal wall relaxes and the diaphragm shifts downward. The abdomen protrudes not because of a massive gas burden, but because the body is handling normal or modest distension abnormally.
That kind of bloating will never be fixed with antibiotics alone. It requires asking sophisticated questions about muscle coordination, visceral hypersensitivity, diaphragmatic mechanics, and pelvic floor dysfunction.
Dysbiosis: Quality Over Quantity
In many patients, the critical issue is not how much bacteria is present, but what kind of microbial community is present. This is called dysbiosis.
A patient may not have dramatic overgrowth, but if their ecosystem is dominated by inflammatory or metabolically problematic organisms, their symptoms will be severe. Conversely, a large microbial burden may not cause symptoms if the composition is favorable.
Think of it like a garden: a garden full of weeds is problematic even if it is not technically overgrown. The composition matters. At ESSI, we believe this is a far more clinically relevant framework than obsessing over overgrowth alone.
The Endometriosis Connection: The ESSI Difference
For patients with endometriosis, the SIBO conversation is even more complicated because bowel symptoms are highly multifactorial. When an endometriosis patient presents to ESSI with bloating, constipation, and abnormal breath testing, we do not simply ask if they have bacterial overgrowth.
We ask:
-
Is there deep endometriosis tethering the bowel?
-
Is there chronic constipation driving stasis?
-
Is there dyssynergic defecation or pelvic floor spasm?
-
Is there a descending perineum or outlet dysfunction?
-
Is there broader gut-brain-pelvis dysregulation?
-
Is SIBO the driver, or merely a passenger?
We do not reduce a complex symptom pattern to one simplistic label.
The Future of GI and Pelvic Care
Our position is straightforward: SIBO is real, but it is commonly overdiagnosed. Breath testing has major limitations. Methane matters, but slow transit matters more. Repeated antibiotics are never an acceptable substitute for true diagnostic reasoning.
The future of good pelvic and GI medicine is not labeling every bloated patient with SIBO and handing out another prescription. The future is understanding exactly what is slowing the bowel, impairing evacuation, and altering the microbiome.
Because when the diagnosis is shallow, treatment becomes repetitive. When the thinking is deeper, treatment becomes smarter.
